PT  - JOURNAL ARTICLE
AU  - Hossein Jadvar
TI  - The VISION Forward: Recognition and Implication of PSMA−/<sup>18</sup>F-FDG+ mCRPC
AID  - 10.2967/jnumed.121.263274
DP  - 2022 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 812--815
VI  - 63
IP  - 6
4099  - http://jnm.snmjournals.org/content/63/6/812.short
4100  - http://jnm.snmjournals.org/content/63/6/812.full
SO  - J Nucl Med2022 Jun 01; 63
AB  - Metastatic castration resistant prostate cancer (mCRPC) is incurable. The expression of the transmembrane protein prostate-specific membrane antigen (PSMA) is markedly increased in most mCRPC lesions. PSMA has been recognized as a viable biologic target for imaging and radionuclide therapy (theranostics) in mCRPC. The PET agents 68Ga-PSMA-11 and 18F-DCFPyL have recently been approved for imaging evaluation of patients with suspected metastasis who are candidates for initial definitive therapy and patients with suspected recurrence based on elevated serum prostate-specific antigen level. Radioligand therapy (RLT) with 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan, Pluvicto, Novartis/AAA) was approved on March 23, 2022, based on the favorable results of the VISION trial. It has been recognized that PET imaging of PSMA expression and glucose metabolism (with 18F-FDG) provides a more comprehensive assessment of the tumor burden and heterogeneity. However, there are many unresolved issues that surround whether or not imaging with 18F-FDG PET is advantageous in the clinical setting of PSMA RLT in mCRPR.